Business
AbbVie Seeks Biotech Acquisition for Eczema Drug
AbbVie is reportedly trying to acquire a biotech company developing an experimental eczema drug for $10.9 billion in cash, according to a Financial Times report.
Coverage timeline — 1 article
MarketWatch
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
2026-06-20 16:11 UTC